Loading...
Market
Market cap of UroGen Pharma by end of 2024
5
Resolution / Starting Odds
Below $1 billion • 33%
$1 billion to $2 billion • 33%
Above $2 billion • 34%
NASDAQ official market cap data
Story
UroGen Pharma Stock Halted, Up 50% After 82.3% Response in Trial
Jun 13, 2024, 03:16 PM
UroGen Pharma's stock ($URGN) was halted after announcing unprecedented results from its ENVISION trial. The trial showed an 82.3% duration of response at 12 months for UGN-102, a potential first FDA-approved non-surgical treatment for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). Following the announcement, $URGN stock spiked 50%, with a trading volume of 5.5 million, 15 times the average daily volume.
View original story
Similar markets
Below $5 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
Above $15 billion • 25%
Below $100M • 33%
$100M-$200M • 33%
Above $200M • 33%
Below $50 • 33%
Between $50 and $100 • 33%
Above $100 • 33%
Exceeds $500 million • 25%
Between $300 million and $500 million • 25%
Between $200 million and $300 million • 25%
Below $200 million • 25%
Increase by 10% or more • 25%
Increase by less than 10% • 25%
No significant change • 25%
Decrease • 25%
Above $1 billion • 33%
Between $500 million and $1 billion • 33%
Below $500 million • 33%
Below $5 billion • 25%
$5 - $7.5 billion • 25%
$7.5 - $10 billion • 25%
Above $10 billion • 25%